ICLE 2022 | Generating CAR-T cells with PiggyBac transposons
Shigeki Yagyu
• 8 Apr 2022
The use of viral vectors in manufacturing chimeric antigen receptor (CAR) T-cells can negatively impact efficacy via T-cell differentiation and exhaustion. Shigeki Yagyu, MD, PhD, Kyoto Prefectural University of Medicine, Kyoto, Japan, discusses the development of PiggyBac transposon-mediated CAR-T cell and its benefits. PiggyBac transposons results in less T-cell exhaustion due to using resting T-cells that are stimulated with CD3 antibodies. Antigen-presenting cells (APCs) with stimulated with IL-7 and IL-13 instead of electroporation additionally results in reduced T-cell death, enhancing the therapeutic viability of CAR T-cells. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
